Court approves $7.25 billion Bayer settlement over Roundup cancer claims
A Missouri judge approved a settlement Friday in which Bayer will pay up to $7.25 billion over two decades to resolve thousands of claims from cancer patients who say the company failed to warn that Roundup weed killer could cause non-Hodgkin lymphoma, according to ABC11.
The settlement covers both people already diagnosed with the cancer and those who may be diagnosed in the future. Participants could receive an average of between $10,000 and $165,000, depending on how they used the product, their age at diagnosis and how severe their illness was, ABC11 reported.
Bayer, a Germany-based company, denies that Roundup causes cancer but agreed to the settlement to gain financial certainty against mounting litigation costs. The company has already changed the formula for Roundup sold to residential users, according to ABC11.
The settlement came after the U.S. Supreme Court ruled in June that Bayer cannot be sued in state courts over failure-to-warn claims about cancer, because federal regulations do not require a cancer warning label and states cannot impose additional labeling requirements, ABC11 reported.
The judge said the average payouts are fair and adequate and the total is among the largest in mass tort personal-injury class action settlement history. The settlement includes $600 million for attorneys' fees, according to ABC11.
